|
|
David H. McDermott, Alan M. Fong, Qiong Yang, Joan M. Sechler, L. Adrienne Cupples, Maya N. Merrell, Peter W.F. Wilson, Ralph B. D’Agostino, Christopher J. O’Donnell, Dhavalkumar D. Patel, Philip M. Murphy
J Clin Invest. 2003;
111(8):1241
doi:10.1172/JCI16790
Abstract |
Full text
| PDF

T
he chemokine receptor CX3CR1 is a proinflammatory leukocyte receptor specific for the chemokine fractalkine (FKN or CX3CL1). In two retrospective studies, CX3CR1 has been implicated in the pathogenesis of atherosclerotic cardiovascular disease (CVD) based on statistical association of a common receptor variant named CX3CR1-M280 with lower prevalence of atherosclerosis, coronary endothelial dysfunction, and acute coronary syndromes. However, the general significance of CX3CR1-M280 and its putative mechanism of action have not previously been defined. Here we show that FKN-dependent cell-cell adhesion under conditions of physiologic shear is severely reduced in cells expressing CX3CR1-M280. This was associated with marked reduction in the kinetics of FKN binding as well as reduced FKN-induced chemotaxis of primary leukocytes from donors homozygous for CX3CR1-M280. We also show that CX3CR1-M280 is independently associated with a lower risk of CVD (adjusted odds ratio, 0.60, P = 0.008) in the Offspring Cohort of the Framingham Heart Study, a long-term prospective study of the risks and natural history of this disease. These data provide mechanism-based and consistent epidemiologic evidence that CX3CR1 may be involved in the pathogenesis of CVD in humans, possibly by supporting leukocyte entry into the coronary artery wall. Moreover, they suggest that CX3CR1-M280 is a genetic risk factor for CVD.
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal.
Not all publishers participate in CrossRef, so this information is not comprehensive.
Additionally, data may not reflect the most current citations to this article,
and the data may differ from citation information available from other sources
(for example, Google Scholar, Web of Science, and Scopus).
Total citations by year
in CrossRef
Citations to this article
in CrossRef
(25)
| Title and authors |
Publication |
Year |
Novel inflammatory mechanisms of accelerated atherosclerosis in kidney disease
Sundararaman Swaminathan, Sudhir V Shah
|
Kidney Int
|
2011 |
The CX3C chemokine fractalkine mediates platelet adhesion via the von Willebrand receptor glycoprotein Ib
S. Meyer dos Santos, U. Klinkhardt, K. Scholich, K. Nelson, N. Monsefi, H. Deckmyn, K. Kuczka, A. Zorn, S. Harder
|
Blood
|
2011 |
Detrimental effect of fractalkine on myocardial ischaemia and heart failure
W. Xuan, Y. Liao, B. Chen, Q. Huang, D. Xu, Y. Liu, J. Bin, M. Kitakaze
|
Cardiovascular Research
|
2011 |
Chemokine ligand CX3CL1
Astrid Cardona, Richard Ransohoff
|
AfCS-Nature Molecule Pages
|
2010 |
Association of Common Polymorphisms in the Fractalkine Receptor (CX3CR1) With Obesity
Dave Sirois-Gagnon, Annie Chamberland, Stéphanie Perron, Diane Brisson, Daniel Gaudet, Catherine Laprise
|
Obesity
|
2010 |
Chemokine receptor CX3CR1
Astrid Cardona, Richard Ransohoff
|
AfCS-Nature Molecule Pages
|
2009 |
Endothelial damage from cytomegalovirus-specific host immune response can be prevented by targeted disruption of fractalkine-CX3CR1 interaction.
Cynthia A Bolovan-Fritts, Stephen A Spector
|
Blood
|
2008 |
The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury.
Li Li, Liping Huang, Sun-Sang J Sung, Amy L Vergis, Diane L Rosin, C Edward Rose, Peter I Lobo, Mark D Okusa
|
Kidney Int
|
2008 |
Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques
Frank Tacke, David Alvarez, Theodore J. Kaplan, Claudia Jakubzick, Rainer Spanbroek, Jaime Llodra, Alexandre Garin, Jianhua Liu, Matthias Mack, Nico van Rooijen, Sergio A. Lira, Andreas J. Habenicht, Gwendalyn J. Randolph
|
J. Clin. Invest.
|
2007 |
Macrophage heterogeneity and tissue lipids
Siamon Gordon
|
J. Clin. Invest.
|
2007 |
|